Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market

Shionogi is about to find out what it takes to get a COVID-19 antiviral to market in Japan. Having missed the primary clinical endpoint in a phase 2b, Shionogi has filed for approval on the strength of evidence its oral antiviral S-217622 reduces viral load and certain symptoms.